RecruitingPhase 1NCT03783416

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.

Sponsor

Queen Mary University of London

Enrollment

72 participants

Start Date

Jun 15, 2020

Study Type

INTERVENTIONAL

Conditions

Relapsing Remitting Multiple Sclerosis Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Summary

The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a drug called ixazomib — originally used in blood cancer treatment — to see if it can reduce abnormal immune cell activity (specifically plasma cells) in people with multiple sclerosis (MS), a disease where the immune system attacks the nervous system. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with multiple sclerosis (either relapsing-remitting or progressive forms) - If you have relapsing-remitting MS, you must be on a disease-modifying therapy (DMT) - If you have progressive MS, you must not currently be on a DMT **You may NOT be eligible if...** - You are outside the age range of 18–65 - You do not meet the specific MS subtype and treatment criteria - You have other health conditions that would make the drug unsafe for you Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.